Australia markets open in 4 hours 51 minutes

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
220.00+3.05 (+1.41%)
At close: 04:00PM EDT
220.68 +0.68 (+0.31%)
After hours: 07:49PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees11,500

Key executives

NameTitlePayExercisedYear born
Mr. Francis A. deSouzaCEO & DirectorN/AN/A1971
Dr. Alexander Aravanis M.D., Ph.D.CTO & Head of Research and Product Devel.1.05MN/A1977
Mr. Charles E. DadswellSr. VP, Gen. Counsel & Sec.N/AN/A1959
Ms. Susan H. TousiChief Commercial Officer1.04MN/A1969
Stephanie CamposPresN/AN/AN/A
Dr. Joydeep Goswami M.B.A., Ph.D.CFO, Chief Strategy & Corp. Devel. OfficerN/AN/A1971
Mr. Kevin Carl PegelsChief of Global OperationsN/AN/AN/A
Mr. Scott EricksenVP & Chief Accounting OfficerN/AN/A1972
Ms. Carissa RollinsChief Information OfficerN/AN/AN/A
Ms. Sallilyn SchwartzVP of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Corporate governance

Illumina, Inc.’s ISS governance QualityScore as of 1 March 2023 is 3. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.